# Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy

> **NCT06418139** · — · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 450 (estimated)

## Conditions studied

- Non-Metastatic Breast Carcinoma

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT06418139
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418139, "Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06418139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*